Plant stanol eaters affect serum cholesterol concentrations of hypercholesterolemic men and women in a dose-dependent manner

Citation
Ma. Hallikainen et al., Plant stanol eaters affect serum cholesterol concentrations of hypercholesterolemic men and women in a dose-dependent manner, J NUTR, 130(4), 2000, pp. 767-776
Citations number
40
Categorie Soggetti
Food Science/Nutrition","Endocrinology, Nutrition & Metabolism
Journal title
JOURNAL OF NUTRITION
ISSN journal
00223166 → ACNP
Volume
130
Issue
4
Year of publication
2000
Pages
767 - 776
Database
ISI
SICI code
0022-3166(200004)130:4<767:PSEASC>2.0.ZU;2-F
Abstract
The effect of plant stanol ester on serum cholesterol is dose-dependent. Ho wever, it is not clear what the dose is beyond which no additional benefit can be obtained. Therefore, we determined the dose-response relationship fo r serum cholesterol with different doses of plant stanol ester in hyperchol esterolemic subjects. In a single-blind design each of 22 men or women cons umed five different doses of plant stanol [target (actual) intake 0 (0), 0. 8 (0.8), 1.6 (1.6), 2.4 (2.3), 3.2 3.0) g/d] added as plant stanol eaters t o margarine for 4 wk. The order of dose periods was randomly determined. Se rum total cholesterol concentration decreased (calculated in reference to c ontrol) by 2.8% (P = 0.384), 6.8% (P < 0.001), 10.3% (P < 0.001) and 11.3% (P < 0.001) by doses from 0.8 to 3.2 g. The respective decreases for LDL ch olesterol were 1.7% (P = 0.892), 5.6% (P < 0.05), 9.7% (P < 0.001) and 10.4 % (P < 0.001). Although the decreases were numerically greater with 2.4 and 3.2 g doses than with the 1.6 g dose, these differences were not significa nt (P = 0.054-0.516). Serum plant stanols rose slightly, but significantly with the dose (P < 0.001). Apolipoprotein B concentration was decreased sig nificantly already at the dose of 0.8 g (8.7%, P < 0.001). Apolipoprotein E genotype did not affect the lipid responses. We conclude that significant reduction of serum total and LDL cholesterol concentrations is reached with the 1.6-g stanol dose, and increasing the dose from 2.4 to 3.2 g does not provide clinically important additional effect.